NCT06735144View on ClinicalTrials.gov

Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 23, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Malignant Solid Tumor
Interventions
DRUG

FH-006

Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days

DRUG

FH-006

administered once every 3 weeks (Q3W), with a treatment period of 21 days

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY